Merck KGaA Research Grants 2026 (Historical Reference): Five Topic Areas and Award Details
Historical reference for Merck KGaA’s 2026 Research Grants call. The 31 August 2026 application deadline has passed, and the official programme page currently shows no later cycle. The closed call offered four research grants with topic-specific cash limits and up to three SYNTHIA® software awards.
Merck KGaA Research Grants 2026 (Historical Reference): Five Topic Areas and Award Details
The 2026 Research Grants call run by Merck KGaA, Darmstadt, Germany is closed. The application deadline published by the programme was 31 August 2026 at 23:59 Central European Summer Time. The official programme page lists the 2026 topics and links to prior calls, but does not announce a later application cycle. This page is therefore an archive reference to the published terms and topics, not an open opportunity. No new deadline should be inferred from the programme’s past annual calls.
The call invited research proposals in five named areas and connected selected researchers with company scientists. Four topics offered cash support with distinct annual limits and durations. A fifth offered SYNTHIA® Retrosynthesis Software access, training, and interaction with Merck scientists rather than a stated cash award. The programme page describes grants of up to €500,000 per year for up to three years as an overall historical programme maximum; that was not the amount available for every topic in this 2026 call. The individual topic limits below are the relevant 2026 figures.
2026 call at a glance
| Item | Published 2026 terms |
|---|---|
| Status | Closed; the listed submission deadline has passed |
| Funder | Merck KGaA, Darmstadt, Germany |
| Application period | 9 January 2026 to 31 August 2026, 23:59 Central European Summer Time |
| Deadline | 31 August 2026, 23:59 Central European Summer Time |
| Eligible applicants | Scientists at all career stages affiliated with a research-based institution, university, or company |
| Geographic scope | The official page describes eligibility by affiliation and does not specify a nationality limit |
| Topic areas | Five, spanning neuroinflammation, cell-culture process modelling, environmental remediation, condensate-based PPI assays, and synthesis/discovery |
| Stage-one submission | Online form with title, abstract, and project-team information; optional explanatory attachments; non-confidential information only |
| Later stages | Invited full proposal under confidentiality, deep-dive workshop, selection, and bilateral collaboration agreement for winners |
| Programme contact | [email protected] |
The official page also says applicants could submit more than one application, provided each was relevant to a research topic. The deadline is retained here as the real historical date. It is not a rolling or ongoing intake, and the archived terms do not establish that late submissions were accepted.
What each topic covered
In-vitro models and assays for neuroinflammatory disease. This topic offered one grant of up to €250,000 per year for up to two years, with the possibility of further collaboration. Merck sought predictive preclinical in-vitro models to identify and optimize small-molecule medicines for human neuroinflammatory diseases. Parkinson’s disease was used to explain the need: the official page describes it as a rapidly growing neurodegenerative disorder, notes that currently approved treatments are symptomatic, and points to limitations in animal-model translation and variation in human pathology. The requested models were to reproduce the cellular microenvironment affected by neuroinflammation, support medium- to high-throughput assays, and allow pharmacological and genomic manipulation. A co-culture containing patient iPSC-derived neurons, astrocytes, oligodendrocytes, and active microglia was offered as an example. The call requested evidence of microglial-neuronal crosstalk, innate immune competence, and dynamic responses to multiple inflammatory stimuli. Suggested readouts included cytokine quantification, morphological changes, and neurotoxic protein aggregation.
Artificial intelligence in cell-culture media and process development. The published limit was one grant of up to €150,000 per year for up to three years, with possible further collaboration. The programme sought robust, host-agnostic, readily parameterized models to speed fit-for-purpose optimization of bioprocesses across host organisms. Merck described mechanistic or hybrid modelling as a way to understand nutrient needs and predict optimized media feeds. It named CHO and HEK293 cells as examples relevant to manufacturing protein therapeutics, vaccines, and cell and gene therapies. A proposal was expected to give a non-confidential description of the model and its key parameters for media optimization, alongside a data strategy for continual improvement and adaptation across mammalian hosts.
Economical remediation of contaminated high-volume materials. This topic offered one grant of up to €150,000 per year for up to two years, with the possibility of further collaboration. It focused on high-volume, low-contamination soil and water, including wastewater and groundwater affected by legacy processes. The specified pollutant focus was chloro-organic compounds, particularly hexachlorocyclohexane (HCH). The call emphasized methods that were innovative, sustainable, scalable, and economically viable. Proposals were explicitly expected to outline practical feasibility for large-scale applications. A bench result without a credible scale-up case would not answer that stated requirement.
Condensate-based cell-free assays for protein-protein interactions. The call offered one grant of up to €100,000 per year for up to three years, with possible further collaboration. It sought sensitive cell-free screening assays using condensate-inspired approaches to study and modulate weak protein-protein interactions (PPIs). The scientific rationale was that conventional screening can lack sensitivity and fail to reproduce cellular conditions, while condensates concentrate proteins and other macromolecules. Applicants were asked to describe anticipated sensitivity improvements and other advantages relative to traditional cell-free methods, and to identify the types of PPIs they aimed to address. The official topic mentioned small-molecule enhancement or disruption of PPIs, including molecular glue degraders and disruption of functional complexes, as relevant contexts.
Advancing molecule synthesis and discovery. This was the non-cash topic. Merck offered up to three awards, each comprising a one-year full SYNTHIA® Retrosynthesis Software license, training, and extensive interaction with company scientists, with an opportunity for further collaboration. The call invited organic synthesis proposals to advance a synthetic project or develop analogue compound libraries, including libraries for structure-activity relationship work. Submitted projects were to be suitable for publication in a peer-reviewed journal and explain how SYNTHIA® would be used. The official page describes the software as combining expert-coded synthesis rules and algorithms, with access to a large database of commercially available starting materials and building blocks.
Who qualified and how proposals were assessed
The programme stated that scientists at all career stages could apply if affiliated with a research-based institution, university, or company. It did not limit eligibility to university faculty. The topic description remained the substantive filter: a project needed to fit one of the five calls and address its requested scientific or practical features. Multiple applications were permitted for distinct relevant topics.
The official FAQ says proposals falling entirely outside the scope of a grant description would be disqualified. It lists six evaluation criteria: innovativeness, commercial potential, path forward after the funding period, probability of success, team strength, and strategic fit. Those criteria mean the call considered both the research concept and its likely development beyond the award period. The terms describe a collaborative research relationship, so the opportunity was designed for teams willing to engage with company scientists as a partner.
Published application and selection process
The application channel was the online submissions platform. The programme FAQ said a first-time applicant needed to register with a valid email address. At stage one, applicants completed the application form with non-confidential information, including the project title, abstract, and team information. Supporting documents or graphics were optional and had no formal format requirements; the FAQ gave PDF and PowerPoint as examples. Applicants had to read and accept the terms and conditions before submission. The FAQ directed people experiencing upload problems to [email protected].
Confidentiality was an important stage boundary. The initial application was limited to non-confidential material. Teams that passed the first evaluation were invited to provide a full proposal under confidentiality and attend a deep-dive workshop. Merck described the workshop as a collaborative step in which invited submitters worked with managers and scientists to optimize their proposals. The FAQ says workshop participants needed to sign a participant’s agreement, present their optimized proposals, and that winners would be selected at the end of the workshop. Applicants should not have placed unpublished inventions, proprietary process details, or other confidential information in the initial form.
The official programme page said teams reaching the workshop stage would be informed in October 2026 and scheduled the workshops for November and December 2026. The FAQ’s more specific answer named November 2026. These were the published prospective selection milestones; they do not establish which applicants were selected or whether any specific award was made. Winning recipients were to enter bilateral collaboration agreements with Merck KGaA, Darmstadt, Germany, to enable payment and project start. The page also says regular meetings with Merck scientists would occur during the funding period. Unsuccessful stage-one applicants were to be notified by email, and the FAQ says detailed feedback would not be available because of application volume.
What this archive can and cannot tell applicants
The call’s amounts, eligibility, topics, and process above are drawn from the official 2026 programme page and its terms and FAQ. They describe that closed cycle. The page does not state that its terms automatically carry into another cycle. A researcher looking for a current opportunity should check Merck’s official Research Grants page for a later call announcement and read that call’s own topic descriptions and terms before preparing a proposal.
The programme page offers a newsletter signup for updates about initiatives and opportunities. It also keeps links to earlier calls. Those are useful routes for tracking future announcements, but they are not evidence that applications are currently open. The application portal link embedded in the 2026 topic page should likewise be treated as part of the closed call unless Merck publishes a new invitation and dates.
This distinction matters because the five 2026 topics were unusually specific. A future edition could offer different research questions, award structures, durations, or application requirements. For example, an archived limit for neuroinflammation should not be reused as a budget assumption for a later topic, and the one-year SYNTHIA® license should not be treated as a standing benefit. Researchers may use the historical call to understand Merck’s open-innovation format, but should not send materials on the assumption that the old form or terms remain active.
Official reference
- Merck KGaA Research Grants: 2026 topics, terms, FAQs, and prior calls
- Programme contact listed for submission-platform issues: [email protected]
The official page is the source for any future cycle announcement. As checked for this update, it shows the 2026 call and prior editions and provides no later deadline. The 2026 application deadline remains 31 August 2026 in this historical record.